Aminopyridines correct early dysfunction and delay neurodegeneration in a mouse model of spinocerebellar ataxia type

Raphael Hourez, Laurent Servais, David Orduz, David Gall, Isabelle Millard, Alban de Kerchove d'Exaerde, Guy Cheron, Harry T. Orr, Massimo Pandolfo, Serge N. Schiffmann

Research output: Contribution to journalArticle

77 Citations (Scopus)

Abstract

The contribution of neuronal dysfunction to neurodegeneration is studied in a mouse model of spinocerebellar ataxia type 1 (SCA1) displaying impaired motor performance ahead of loss or atrophy of cerebellar Purkinje cells. Presymptomatic SCA1 mice show a reduction in the firing rate of Purkinje cells (both in vivo and in slices) associated with a reduction in the efficiency of the main glutamatergic synapse onto Purkinje cells and with increased A-type potassium current. The A-type potassium channel Kv4.3 appears to be internalized in response to glutamatergic stimulation in Purkinje cells and accumulates in presymptomatic SCA1 mice. SCA1 mice are treated with aminopyridines, acting as potassium channel blockers to test whether the treatment could improve neuronal dysfunction, motor behavior, and neurodegeneration. In acutely treated young SCA1 mice, aminopyridines normalize the firing rate of Purkinje cells and the motor behavior of the animals. In chronically treated old SCA1 mice, 3,4-diaminopyridine improves the firing rate of Purkinje cells, the motor behavior of the animals, and partially protects against cell atrophy. Chronic treatment with 3,4-diaminopyridine is associated with increased cerebellar levels of BDNF, suggesting that partial protection against atrophy of Purkinje cells is possibly provided by an increased production of growth factors secondary to the reincrease in electrical activity. Our data suggest that aminopyridines might have symptomatic and/or neuroprotective beneficial effects in SCA1, that reduction in the firing rate of Purkinje cells can cause cerebellar ataxia, and that treatment of early neuronal dysfunction is relevant in neurodegenerative disorders such as SCA1.

Original languageEnglish (US)
Pages (from-to)11795-11807
Number of pages13
JournalJournal of Neuroscience
Volume31
Issue number33
DOIs
StatePublished - Aug 17 2011

Fingerprint

Aminopyridines
Spinocerebellar Ataxias
Purkinje Cells
Atrophy
Animal Behavior
Shal Potassium Channels
Potassium Channel Blockers
Cerebellar Ataxia
Brain-Derived Neurotrophic Factor
Neuroprotective Agents
Neurodegenerative Diseases
Synapses
Intercellular Signaling Peptides and Proteins
Potassium

Cite this

Hourez, R., Servais, L., Orduz, D., Gall, D., Millard, I., de Kerchove d'Exaerde, A., ... Schiffmann, S. N. (2011). Aminopyridines correct early dysfunction and delay neurodegeneration in a mouse model of spinocerebellar ataxia type. Journal of Neuroscience, 31(33), 11795-11807. https://doi.org/10.1523/JNEUROSCI.0905-11.2011

Aminopyridines correct early dysfunction and delay neurodegeneration in a mouse model of spinocerebellar ataxia type. / Hourez, Raphael; Servais, Laurent; Orduz, David; Gall, David; Millard, Isabelle; de Kerchove d'Exaerde, Alban; Cheron, Guy; Orr, Harry T.; Pandolfo, Massimo; Schiffmann, Serge N.

In: Journal of Neuroscience, Vol. 31, No. 33, 17.08.2011, p. 11795-11807.

Research output: Contribution to journalArticle

Hourez, R, Servais, L, Orduz, D, Gall, D, Millard, I, de Kerchove d'Exaerde, A, Cheron, G, Orr, HT, Pandolfo, M & Schiffmann, SN 2011, 'Aminopyridines correct early dysfunction and delay neurodegeneration in a mouse model of spinocerebellar ataxia type', Journal of Neuroscience, vol. 31, no. 33, pp. 11795-11807. https://doi.org/10.1523/JNEUROSCI.0905-11.2011
Hourez, Raphael ; Servais, Laurent ; Orduz, David ; Gall, David ; Millard, Isabelle ; de Kerchove d'Exaerde, Alban ; Cheron, Guy ; Orr, Harry T. ; Pandolfo, Massimo ; Schiffmann, Serge N. / Aminopyridines correct early dysfunction and delay neurodegeneration in a mouse model of spinocerebellar ataxia type. In: Journal of Neuroscience. 2011 ; Vol. 31, No. 33. pp. 11795-11807.
@article{f352e42f70ba4bacb75bf016c9c6462a,
title = "Aminopyridines correct early dysfunction and delay neurodegeneration in a mouse model of spinocerebellar ataxia type",
abstract = "The contribution of neuronal dysfunction to neurodegeneration is studied in a mouse model of spinocerebellar ataxia type 1 (SCA1) displaying impaired motor performance ahead of loss or atrophy of cerebellar Purkinje cells. Presymptomatic SCA1 mice show a reduction in the firing rate of Purkinje cells (both in vivo and in slices) associated with a reduction in the efficiency of the main glutamatergic synapse onto Purkinje cells and with increased A-type potassium current. The A-type potassium channel Kv4.3 appears to be internalized in response to glutamatergic stimulation in Purkinje cells and accumulates in presymptomatic SCA1 mice. SCA1 mice are treated with aminopyridines, acting as potassium channel blockers to test whether the treatment could improve neuronal dysfunction, motor behavior, and neurodegeneration. In acutely treated young SCA1 mice, aminopyridines normalize the firing rate of Purkinje cells and the motor behavior of the animals. In chronically treated old SCA1 mice, 3,4-diaminopyridine improves the firing rate of Purkinje cells, the motor behavior of the animals, and partially protects against cell atrophy. Chronic treatment with 3,4-diaminopyridine is associated with increased cerebellar levels of BDNF, suggesting that partial protection against atrophy of Purkinje cells is possibly provided by an increased production of growth factors secondary to the reincrease in electrical activity. Our data suggest that aminopyridines might have symptomatic and/or neuroprotective beneficial effects in SCA1, that reduction in the firing rate of Purkinje cells can cause cerebellar ataxia, and that treatment of early neuronal dysfunction is relevant in neurodegenerative disorders such as SCA1.",
author = "Raphael Hourez and Laurent Servais and David Orduz and David Gall and Isabelle Millard and {de Kerchove d'Exaerde}, Alban and Guy Cheron and Orr, {Harry T.} and Massimo Pandolfo and Schiffmann, {Serge N.}",
year = "2011",
month = "8",
day = "17",
doi = "10.1523/JNEUROSCI.0905-11.2011",
language = "English (US)",
volume = "31",
pages = "11795--11807",
journal = "Journal of Neuroscience",
issn = "0270-6474",
publisher = "Society for Neuroscience",
number = "33",

}

TY - JOUR

T1 - Aminopyridines correct early dysfunction and delay neurodegeneration in a mouse model of spinocerebellar ataxia type

AU - Hourez, Raphael

AU - Servais, Laurent

AU - Orduz, David

AU - Gall, David

AU - Millard, Isabelle

AU - de Kerchove d'Exaerde, Alban

AU - Cheron, Guy

AU - Orr, Harry T.

AU - Pandolfo, Massimo

AU - Schiffmann, Serge N.

PY - 2011/8/17

Y1 - 2011/8/17

N2 - The contribution of neuronal dysfunction to neurodegeneration is studied in a mouse model of spinocerebellar ataxia type 1 (SCA1) displaying impaired motor performance ahead of loss or atrophy of cerebellar Purkinje cells. Presymptomatic SCA1 mice show a reduction in the firing rate of Purkinje cells (both in vivo and in slices) associated with a reduction in the efficiency of the main glutamatergic synapse onto Purkinje cells and with increased A-type potassium current. The A-type potassium channel Kv4.3 appears to be internalized in response to glutamatergic stimulation in Purkinje cells and accumulates in presymptomatic SCA1 mice. SCA1 mice are treated with aminopyridines, acting as potassium channel blockers to test whether the treatment could improve neuronal dysfunction, motor behavior, and neurodegeneration. In acutely treated young SCA1 mice, aminopyridines normalize the firing rate of Purkinje cells and the motor behavior of the animals. In chronically treated old SCA1 mice, 3,4-diaminopyridine improves the firing rate of Purkinje cells, the motor behavior of the animals, and partially protects against cell atrophy. Chronic treatment with 3,4-diaminopyridine is associated with increased cerebellar levels of BDNF, suggesting that partial protection against atrophy of Purkinje cells is possibly provided by an increased production of growth factors secondary to the reincrease in electrical activity. Our data suggest that aminopyridines might have symptomatic and/or neuroprotective beneficial effects in SCA1, that reduction in the firing rate of Purkinje cells can cause cerebellar ataxia, and that treatment of early neuronal dysfunction is relevant in neurodegenerative disorders such as SCA1.

AB - The contribution of neuronal dysfunction to neurodegeneration is studied in a mouse model of spinocerebellar ataxia type 1 (SCA1) displaying impaired motor performance ahead of loss or atrophy of cerebellar Purkinje cells. Presymptomatic SCA1 mice show a reduction in the firing rate of Purkinje cells (both in vivo and in slices) associated with a reduction in the efficiency of the main glutamatergic synapse onto Purkinje cells and with increased A-type potassium current. The A-type potassium channel Kv4.3 appears to be internalized in response to glutamatergic stimulation in Purkinje cells and accumulates in presymptomatic SCA1 mice. SCA1 mice are treated with aminopyridines, acting as potassium channel blockers to test whether the treatment could improve neuronal dysfunction, motor behavior, and neurodegeneration. In acutely treated young SCA1 mice, aminopyridines normalize the firing rate of Purkinje cells and the motor behavior of the animals. In chronically treated old SCA1 mice, 3,4-diaminopyridine improves the firing rate of Purkinje cells, the motor behavior of the animals, and partially protects against cell atrophy. Chronic treatment with 3,4-diaminopyridine is associated with increased cerebellar levels of BDNF, suggesting that partial protection against atrophy of Purkinje cells is possibly provided by an increased production of growth factors secondary to the reincrease in electrical activity. Our data suggest that aminopyridines might have symptomatic and/or neuroprotective beneficial effects in SCA1, that reduction in the firing rate of Purkinje cells can cause cerebellar ataxia, and that treatment of early neuronal dysfunction is relevant in neurodegenerative disorders such as SCA1.

UR - http://www.scopus.com/inward/record.url?scp=80051770615&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80051770615&partnerID=8YFLogxK

U2 - 10.1523/JNEUROSCI.0905-11.2011

DO - 10.1523/JNEUROSCI.0905-11.2011

M3 - Article

C2 - 21849540

AN - SCOPUS:80051770615

VL - 31

SP - 11795

EP - 11807

JO - Journal of Neuroscience

JF - Journal of Neuroscience

SN - 0270-6474

IS - 33

ER -